CSS
PCSA icon

Cubist Systematic Strategies’s Processa Pharmaceuticals PCSA Stock Holding History

Cubist Systematic Strategies’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,674
Closed -$8.58K – 3410
2025
Q2 		$8.58K Buy
+1,674
New +$11.2K ﹤0.01% 2842

Other funds holding PCSA

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
SCA
Sassicaia Capital Advisers Jericho, New York $227M AUM 402.2% 1-Year Est. Return
MMA
Miracle Mile Advisors Los Angeles, California $8.53B AUM 21.43% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Cubist Systematic Strategies's PCSA Position: Q3 2025 in Review

Cubist Systematic Strategies sold out of Processa Pharmaceuticals (PCSA) in Q3 2025, closing a stake of 1,674 shares — an estimated $8.58K sold.

Cubist Systematic Strategies first reported a position in PCSA in Q2 2025 and held it in 1 quarter. The position peaked at $8.58K in Q2 2025. 13 funds tracked by Wall St. Rank hold PCSA as of Q3 2025.

  • Cubist Systematic Strategies reported no remaining Processa Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 1,674 Processa Pharmaceuticals shares in Q3 2025, an estimated $8.58K.
  • Cubist Systematic Strategies first reported a position in Processa Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Cubist Systematic Strategies's Processa Pharmaceuticals position peaked at $8.58K in Q2 2025.
  • 13 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.